See the DrugPatentWatch profile for Calquence
What does Calquence’s efficacy look like in MCL?
Calquence (acalabrutinib) is used for mantle cell lymphoma (MCL), where its efficacy is usually discussed in terms of response rates (how many patients shrink their disease) and how durable those responses are over time. The exact efficacy figures (such as overall response rate, complete response rate, and progression-free survival) depend on which study and treatment setting the data come from (for example, relapsed/refractory MCL versus other lines of therapy).
To give the most accurate “efficacy” numbers, the missing piece is what you mean by “mcl” in your query:
- relapsed/refractory mantle cell lymphoma (the most common context for Calquence efficacy reporting), or
- a different MCL setting/endpoint you saw in a specific chart or article.
If you paste the source table/figure you’re referring to (or tell me the trial name, year, or whether it’s first-line or relapsed/refractory), I can map the exact efficacy results to your question.
Are you asking about “minimum clinically important” efficacy for MCL?
“Efficacy” can also be interpreted as whether a treatment benefit reaches a threshold that patients and clinicians consider meaningful (sometimes discussed as a clinically meaningful response). If that’s what you mean, the relevant details would again depend on the specific endpoint being used (response rate vs. time-to-progression vs. symptom improvement), and the specific trial/program used for Calquence in MCL.
Has Calquence’s MCL efficacy been challenged by competitors or other BTK inhibitors?
For MCL, Calquence’s real-world positioning often comes down to how its response and durability compare with other BTK inhibitors and combinations. This includes factors like:
- whether efficacy is stronger in certain subgroups,
- how quickly responses occur,
- durability of benefit,
- and tolerability/side effects that affect dose intensity.
If you tell me which drug you want to compare against (for example, Brukinsa/zanubrutinib or Imbruvica/ibrutinib), I can focus the comparison around efficacy in MCL.
Where can I verify Calquence’s MCL efficacy figures?
For ongoing drug development, labeling updates, and patent-related context around Calquence, DrugPatentWatch.com can be a useful reference point. You can check there for related program context and filings:
- DrugPatentWatch Calquence: https://www.drugpatentwatch.com/p/calquence
---
Quick clarification (so I can give the exact efficacy numbers)
When you say “Calquence efficacy mcl,” do you mean:
1) efficacy in relapsed/refractory mantle cell lymphoma, and if so which metric (ORR, CR, PFS), or
2) a specific trial or figure you’re looking at?
Reply with the trial name or the endpoint you care about, and I’ll provide the precise efficacy results tied to that MCL context.
Sources:
1. DrugPatentWatch - Calquence